Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Martino EA, Mauro FR, Reda G, Laurenti L, Visentin A, Frustaci A, Vigna E, Pepe S, Catania G, Loseto G, Murru R, Chiarenza A, Sportoletti P, Del Principe MI, Laureana R, Coscia M, Galimberti S, Ferretti E, Zucchetto A, Bomben R, Polesel J, Tedeschi A, Rossi D, Trentin L, Neri A, Morabito F, Gattei V, Gentile M. Martino EA, et al. Hematol Oncol. 2024 Jan;42(1):e3249. doi: 10.1002/hon.3249. Hematol Oncol. 2024. PMID: 38287529
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR, Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R, Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini M, Trentin L, Gattei V, Morabito F. Gentile M, et al. Among authors: martino ea. Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3. Blood Cancer J. 2020. PMID: 32938904 Free PMC article. No abstract available.
Chemotherapy-based regimens in multiple myeloma in 2020.
Gentile M, Morabito F, Martino M, Vigna E, Martino EA, Mendicino F, Martinelli G, Cerchione C. Gentile M, et al. Among authors: martino ea, martino m. Panminerva Med. 2021 Mar;63(1):7-12. doi: 10.23736/S0031-0808.20.04145-2. Epub 2020 Sep 21. Panminerva Med. 2021. PMID: 32955186 Free article. Review.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Mendicino F, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Cutrona G, Jaksic O, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: martino ea. Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28. Eur J Haematol. 2021. PMID: 33378569 Free article.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Vigna E, Martino EA, Mendicino F, Botta C, Caracciolo D, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: martino ea. Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24. Am J Hematol. 2021. PMID: 33580969 Free article. No abstract available.
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
Morabito F, Tripepi G, Vigna E, Bossio S, D'Arrigo G, Martino EA, Storino F, Recchia AG, Fronza G, Di Raimondo F, Colombo M, Fais F, Neri A, Cutrona G, Ferrarini M, Gentile M. Morabito F, et al. Among authors: martino ea. Eur J Haematol. 2021 Jun;106(6):831-835. doi: 10.1111/ejh.13614. Epub 2021 Apr 7. Eur J Haematol. 2021. PMID: 33662164 Free article. Clinical Trial.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: martino ea. Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3. Am J Hematol. 2021. PMID: 33878220 Free article. No abstract available.
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F, Gentile M. Botta C, et al. Among authors: martino ea. Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021. Front Oncol. 2021. PMID: 33937048 Free PMC article. No abstract available.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Recchia AG, Rossi FM, Zucchetto A, Al-Janazreh H, Martino EA, Vigna E, Tripepi G, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Jaksic O, Olivieri J, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: martino ea. Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25. Am J Hematol. 2021. PMID: 33989438 Free article. No abstract available.
76 results